Fecal microbial composition of ulcerative colitis and Crohn's disease patients in remission and subsequent exacerbation

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Wills, Edgar S ^a   Jonkers, Daisy M A E ^a   Savelkoul, Paul H ^a   Masclee, Ad A ^a   Pierik, Marieke J ^a   Penders, John ^a,b  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CALGRANULIN; DNA 16S; METHOTREXATE; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; ANTIMETABOLITE; IMMUNOLOGIC FACTOR; MERCAPTOPURINE; RNA 16S; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; COLONOSCOPY; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; DISEASE EXACERBATION; DNA SEQUENCE; FECES MICROFLORA; FEMALE; HUMAN; MALE; MICROBIAL DIVERSITY; POPULATION ABUNDANCE; PRINCIPAL COORDINATE ANALYSIS; PROSPECTIVE STUDY; PYROSEQUENCING; REMISSION; SPECIES RICHNESS; TAXONOMY; ULCERATIVE COLITIS; YOUNG ADULT; ANTAGONISTS AND INHIBITORS; COLITIS, ULCERATIVE; DISEASE COURSE; FECES; GENETIC VARIABILITY; GENETICS; INTESTINE; MICROBIOLOGY; MICROFLORA; MIDDLE AGED; PATHOLOGY; RECURRENT DISEASE;

6-MERCAPTOPURINE; ADULT; AGED; ANTIMETABOLITES; COLITIS, ULCERATIVE; CROHN DISEASE; DISEASE PROGRESSION; FECES; FEMALE; GENETIC VARIATION; HUMANS; IMMUNOLOGIC FACTORS; INTESTINES; MALE; MICROBIOTA; MIDDLE AGED; PROSPECTIVE STUDIES; RECURRENCE; REMISSION INDUCTION; RNA, RIBOSOMAL, 16S; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84897377243     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0090981     Document Type: Article

References (52)

1. Scharl M, Rogler G (2012) Inflammatory bowel disease pathogenesis: what is new? Curr Opin Gastroenterol 28: 301-309.
2. Blumenstein I, Bock H, Weber C, Rambow A, Tacke W, et al. (2008) Health care and cost of medication for inflammatory bowel disease in the Rhein-Main region, Germany: a multicenter, prospective, internet-based study. Inflamm Bowel Dis 14: 53-60. (Pubitemid 351196869)
3. Buchanan J, Wordsworth S, Ahmad T, Perrin A, Vermeire S, et al. (2011) Managing the long term care of inflammatory bowel disease patients: The cost to European health care providers. J Crohns Colitis 5: 301-316.
4. van der Valk ME, Mangen MJ, Leenders M, Dijkstra G, van Bodegraven AA, et al. (2014) Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFalpha therapy: results from the COIN study. Gut.
5. Talley NJ, Abreu MT, Achkar JP, Bernstein CN, Dubinsky MC, et al. (2011) An evidence-based systematic review on medical therapies for inflammatory bowel disease. Am J Gastroenterol 106 Suppl 1: S2-25; quiz S26.
6. Frank DN, St Amand AL, Feldman RA, Boedeker EC, Harpaz N, et al. (2007) Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci U S A 104: 13780-13785. (Pubitemid 350003397)
7. Swidsinski A, Loening-Baucke V, Vaneechoutte M, Doerffel Y (2008) Active Crohn's disease and ulcerative colitis can be specifically diagnosed and monitored based on the biostructure of the fecal flora. Inflamm Bowel Dis 14: 147-161. (Pubitemid 351288036)
8. Takaishi H, Matsuki T, Nakazawa A, Takada T, Kado S, et al. (2008) Imbalance in intestinal microflora constitution could be involved in the pathogenesis of inflammatory bowel disease. Int J Med Microbiol 298: 463-472. (Pubitemid 351734793)
9. Sokol H, Seksik P, Furet JP, Firmesse O, Nion-Larmurier I, et al. (2009) Low counts of Faecalibacterium prausnitzii in colitis microbiota. Inflamm Bowel Dis 15: 1183-1189.
10. Eckburg PB, Bik EM, Bernstein CN, Purdom E, Dethlefsen L, et al. (2005) Diversity of the human intestinal microbial flora. Science 308: 1635-1638. (Pubitemid 40807514)
11. Sokol H, Seksik P, Rigottier-Gois L, Lay C, Lepage P, et al. (2006) Specificities of the fecal microbiota in inflammatory bowel disease. Inflamm Bowel Dis 12: 106-111.
12. Rehman A, Lepage P, Nolte A, Hellmig S, Schreiber S, et al. (2010) Transcriptional activity of the dominant gut mucosal microbiota in chronic inflammatory bowel disease patients. J Med Microbiol 59: 1114-1122.
13. Seksik P, Rigottier-Gois L, Gramet G, Sutren M, Pochart P, et al. (2003) Alterations of the dominant faecal bacterial groups in patients with Crohn's disease of the colon. Gut 52: 237-242. (Pubitemid 36115065)
14. Sokol H, Lay C, Seksik P, Tannock GW (2008) Analysis of bacterial bowel communities of IBD patients: what has it revealed? Inflamm Bowel Dis 14: 858-867. (Pubitemid 351898071)
15. Martinez-Medina M, Aldeguer X, Gonzalez-Huix F, Acero D, Garcia-Gil LJ (2006) Abnormal microbiota composition in the ileocolonic mucosa of Crohn's disease patients as revealed by polymerase chain reaction-denaturing gradient gel electrophoresis. Inflamm Bowel Dis 12: 1136-1145. (Pubitemid 44847471)
16. Kotlowski R, Bernstein CN, Sepehri S, Krause DO (2007) High prevalence of Escherichia coli belonging to the B2+D phylogenetic group in inflammatory bowel disease. Gut 56: 669-675. (Pubitemid 46662933)
17. Willing BP, Dicksved J, Halfvarson J, Andersson AF, Lucio M, et al. (2010) A pyrosequencing study in twins shows that gastrointestinal microbial profiles vary with inflammatory bowel disease phenotypes. Gastroenterology 139: 1844-1854 e1841.
18. Nagalingam NA, Lynch SV (2011) Role of the microbiota in inflammatory bowel diseases. Inflamm Bowel Dis.
19. Rajilic-Stojanovic M, Shanahan F, Guarner F, de Vos WM (2013) Phylogenetic analysis of dysbiosis in ulcerative colitis during remission. Inflamm Bowel Dis 19: 481-488.
20. Andoh A, Imaeda H, Aomatsu T, Inatomi O, Bamba S, et al. (2011) Comparison of the fecal microbiota profiles between ulcerative colitis and Crohn's disease using terminal restriction fragment length polymorphism analysis. J Gastroenterol 46: 479-486.
21. Sepehri S, Kotlowski R, Bernstein CN, Krause DO (2007) Microbial diversity of inflamed and noninflamed gut biopsy tissues in inflammatory bowel disease. Inflamm Bowel Dis 13: 675-683. (Pubitemid 46909981)
22. Bibiloni R, Mangold M, Madsen KL, Fedorak RN, Tannock GW (2006) The bacteriology of biopsies differs between newly diagnosed, untreated, Crohn's disease and ulcerative colitis patients. J Med Microbiol 55: 1141-1149. (Pubitemid 44215574)
23. Gophna U, Sommerfeld K, Gophna S, Doolittle WF, Veldhuyzen van Zanten SJ (2006) Differences between tissue-associated intestinal microfloras of patients with Crohn's disease and ulcerative colitis. J Clin Microbiol 44: 4136-4141. (Pubitemid 44737260)
24. Swidsinski A, Weber J, Loening-Baucke V, Hale LP, Lochs H (2005) Spatial organization and composition of the mucosal flora in patients with inflammatory bowel disease. J Clin Microbiol 43: 3380-3389. (Pubitemid 40981351)
25. Ott SJ, Musfeldt M, Wenderoth DF, Hampe J, Brant O, et al. (2004) Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease. Gut 53: 685-693. (Pubitemid 38561447)
26. Manichanh C, Rigottier-Gois L, Bonnaud E, Gloux K, Pelletier E, et al. (2006) Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach. Gut 55: 205-211. (Pubitemid 43117279)
27. Mylonaki M, Rayment NB, Rampton DS, Hudspith BN, Brostoff J (2005) Molecular characterization of rectal mucosa-associated bacterial flora in inflammatory bowel disease. Inflamm Bowel Dis 11: 481-487. (Pubitemid 40704083)
28. Ohkusa T, Sato N, Ogihara T, Morita K, Ogawa M, et al. (2002) Fusobacterium varium localized in the colonic mucosa of patients with ulcerative colitis stimulates species-specific antibody. J Gastroenterol Hepatol 17: 849-853.
29. Morgan XC, Tickle TL, Sokol H, Gevers D, Devaney KL, et al. (2012) Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol 13: R79.
30. Masclee GM, Penders J, Pierik M, Wolffs P, Jonkers D (2013) Enteropathogenic Viruses: Triggers for Exacerbation in IBD? A Prospective Cohort Study Using Real-time Quantitative Polymerase Chain Reaction. Inflamm Bowel Dis 19: 124-131.
31. Lennard-Jones JE (1989) Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl 170: 2-6; discussion 16-19.
32. af Bjorkesten CG, Nieminen U, Turunen U, Arkkila P, Sipponen T, et al. (2012) Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-TNF-treated luminal Crohn's disease. Scand J Gastroenterol 47: 528-537.
33. Regueiro M, Kip KE, Schraut W, Baidoo L, Sepulveda AR, et al. (2011) Crohn's disease activity index does not correlate with endoscopic recurrence one year after ileocolonic resection. Inflamm Bowel Dis 17: 118-126.
34. Dethlefsen L, Huse S, Sogin ML, Relman DA (2008) The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. PLoS Biol 6: e280.
35. Schloss PD, Westcott SL, Ryabin T, Hall JR, Hartmann M, et al. (2009) Introducing mothur: open-source, platform-independent, community-supported software for describing and comparing microbial communities. Appl Environ Microbiol 75: 7537-7541.
36. Caporaso JG, Kuczynski J, Stombaugh J, Bittinger K, Bushman FD, et al. (2010) QIIME allows analysis of high-throughput community sequencing data. Nat Methods 7: 335-336.
37. McDonald D, Price MN, Goodrich J, Nawrocki EP, DeSantis TZ, et al. (2011) An improved Greengenes taxonomy with explicit ranks for ecological and evolutionary analyses of bacteria and archaea. ISME J 6: 610-618.
38. Lozupone C, Knight R (2005) UniFrac: a new phylogenetic method for comparing microbial communities. Appl Environ Microbiol 71: 8228-8235. (Pubitemid 41803949)
39. Lladser ME, Gouet R, Reeder J (2011) Extrapolation of urn models via poissonization: accurate measurements of the microbial unknown. PLoS One 6: e21105.
40. Clarke K (1993) Non-parametric multivariate analyses of changes in community structure. Austral J Ecol 18: 117-143.
41. Sandborn WJ (2001) Rational dosing of azathioprine and 6-mercaptopurine. Gut 48: 591-592.
42. Nam YD, Jung MJ, Roh SW, Kim MS, Bae JW (2011) Comparative analysis of Korean human gut microbiota by barcoded pyrosequencing. PLoS One 6: e22109.
43. Claesson MJ, O'Sullivan O, Wang Q, Nikkila J, Marchesi JR, et al. (2009) Comparative analysis of pyrosequencing and a phylogenetic microarray for exploring microbial community structures in the human distal intestine. PLoS One 4: e6669.
44. van den Bogert B, de Vos WM, Zoetendal EG, Kleerebezem M (2011) Microarray analysis and barcoded pyrosequencing provide consistent microbial profiles depending on the source of human intestinal samples. Appl Environ Microbiol 77: 2071-2080.
45. Vaughn BP, Shah S, Cheifetz AS (2014) The Role of Mucosal Healing in the Treatment of Patients With Inflammatory Bowel Disease. Curr Treat Options Gastroenterol.
46. Kaser A, Zeissig S, Blumberg RS (2010) Genes and environment: how will our concepts on the pathophysiology of IBD develop in the future? Dig Dis 28: 395-405.
47. Young VB, Kahn SA, Schmidt TM, Chang EB (2011) Studying the Enteric Microbiome in Inflammatory Bowel Diseases: Getting through the Growing Pains and Moving Forward. Front Microbiol 2: 144.
48. Prindiville TP, Sheikh RA, Cohen SH, Tang YJ, Cantrell MC, et al. (2000) Bacteroides fragilis enterotoxin gene sequences in patients with inflammatory bowel disease. Emerg Infect Dis 6: 171-174. (Pubitemid 30226895)
49. Rabizadeh S, Rhee KJ, Wu S, Huso D, Gan CM, et al. (2007) Enterotoxigenic bacteroides fragilis: a potential instigator of colitis. Inflamm Bowel Dis 13: 1475-1483.
50. Patrick S, Blakely GW (2012) Crossing the eukaryote-prokaryote divide: A ubiquitin homolog in the human commensal bacterium Bacteroides fragilis. Mob Genet Elements 2: 149-151.
51. Greenstein RJ, Su L, Haroutunian V, Shahidi A, Brown ST (2007) On the action of methotrexate and 6-mercaptopurine on M. avium subspecies paratuberculosis. PLoS One 2: e161.
52. Shin SJ, Collins MT (2008) Thiopurine drugs azathioprine and 6-mercaptopurine inhibit Mycobacterium paratuberculosis growth in vitro. Antimicrob Agents Chemother 52: 418-426.